Multiple Myeloma

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss key implications from the phase 2 MASTER trial, utilizing daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.

Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how he would like to see the OCEAN trial and Melflufen progress for relapsed/refractory multiple myeloma.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most common adverse effects experienced from the quadruplet drug treatment for patients with multiple myeloma.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss the differences in safety profiles between melflufen/dexamethasone and pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma.

Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.

Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the decision to start the phase 2 MASTER trial for multiple myeloma.

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss key data that read out from the OCEAN trial for relapsed/refractory multiple myeloma.

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

Fredrik Schjesvold, MD, PhD, speaks about the FDA approval of melflufen in relapsed/refractory multiple myeloma and its next phase of development at the 2021 International Myeloma Workshop.

The latest episode of the ASTCT Talks features Rahul Banerjee, MD, on bone marrow transplant and CAR-T therapy.

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

Patients with newly diagnosed multiple myeloma experienced rapid responses and notable rates of minimal residual disease negativity following minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Patients with relapsed/refractory multiple myeloma who were treated with the recommended phase 2 dose of talquetamab experienced positive clinical activity.

Continued efficacy of CAR T-cell therapy with idecabtagene vicleucel in patients with pretreated myeloma is evidenced by updated KarMMa trial findings presented at the 18th International Myeloma Workshop.